Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) support and resistance · P/E 44, rev $2.79B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
This page maps Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new AMRX 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the AMRX quote page for the session range and the stock page for the full model.
Not investment advice.